Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response

International Journal of Cancer

Volumn 123, Issue 12, 2008, Pages 2832-2839

  Cassard, Lydie ^a,b,c,i   Cohen Solal, Joel F G ^a,b,c,j   Fournier, Emilie M ^a,b,c   Camilleri Broët, Sophie ^a,b,c,d   Spatz, Alain ^e   Chouaïb, Salem ^e   Badoual, Cécile ^a,b,c   Varin, Audrey ^a,b,c   Fisson, Sylvain ^a,b,c   Duvillard, Pierre ^e   Boix, Charlotte ^a,b,c   Loncar, Shannon M ^a   Sastre Garau, Xavier ^f   Houghton, Alan N ^g   Avril, Marie Françoise ^h   Gresser, Ion ^a,b,c   Fridman, Wolf H ^a,b,c   Sautès Fridman, Catherine ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔTEL DIEU   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT CURIE   (France)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h National Institute of Health ^*  (France)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

more..

Author keywords

Antibodies; Cytotoxicity; Fc receptors; Immune escape; Melanoma

Indexed keywords

FC RECEPTOR IIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MELANOMA B16; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; RECEPTORS, IGG; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 57349198014     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23870     Document Type: Article

References (56)

1. Clark WH, Jr, Elder DE, Guerry DT, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-65.
2. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001;13:134-40.
3. Anichini A, Vegetti C, Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 2004;53:855-64.
4. Canevari S, Pupa SM, Menard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 1996;7:227-32.
5. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
7. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
8. Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van Endert P, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A, Galon J, Raposo G, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 2006;103:1428-33.
9. Radfar S, Davrinche C, Hollande E. Serial in vivo loss and in vitro gain of Fas expression and function in human cancerous pancreatic duct cells. Int J Cancer 2005;115:214-23.
10. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ, Jr. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997;7:83-95.
11. Watanabe T, Pukel CS, Takeyama H, Lloyd KO, Shiku H, Li LT, Travassos LR, Oettgen HF, Old LJ. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 1982;156:1884-9.
12. Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982;79:7629-33.
13. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989;49:5091-6.
14. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
15. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 2000;85:659-66.
16. Lutzky J, Gonzalez-Angulo AM, Orzano JA. Antibody-based vaccines for the treatment of melanoma. Semin Oncol 2002;29:462-70.
17. Ehlken H, Schadendorf D, Eichmuller S. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 2004;108:307-13.
18. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, Malo M. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 1995;61:548-56.
19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
20. Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 2006;55:761-74.
21. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002;51:9-14.
22. Fridman WH, Bonnerot C, Daeron M, Amigorena S, Teillaud JL, Sautes C. Structural bases of Fc gamma receptor functions. Immunol Rev 1992;125:49-76.
23. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006;24:19-28.
24. Deo YM, Graziano RF, Repp R, van de Winkel JG. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997;18:127-35.
25. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994;57:1-127.
26. Cassard L, Cohen-Solal JF, Galinha A, Sastre-Garau X, Mathiot C, Galon J, Dorval T, Bernheim A, Fridman WH, Sautes-Fridman C. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest 2002;110:1549-57.
27. Camilleri-Broet S, Cassard L, Broet P, Delmer A, Le Touneau A, Diebold J, Fridman WH, Molina TJ, Sautes-Fridman C. FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 2004;124:55-62.
28. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990;171:1375-80.
29. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983;62:873-82.
30. Merimsky O, Shoenfeld Y, Chaitchik S, Yecheskel G, Fishman P. Antigens and antibodies in malignant melanoma. Tumour Biol 1994;15:188-202.
31. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-54.
32. Klugewitz K, Adams DH, Emoto M, Eulenburg K, Hamann A. The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol 2004;25:590-4.
33. Amigorena S, Bonnerot C, Drake JR, Choquet D, Hunziker W, Guillet JG, Webster P, Sautes C, Mellman I, Fridman WH. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 1992;256:1808-12.
34. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14.
35. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95:652-6.
36. Zusman T, Gohar O, Eliassi H, Avivi Y, Lisansky E, Sautes C, Even J, Bonnerot C, Fridman WH, Witz IP, Ran M. The murine Fc-gamma (Fc gamma) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus-transformed 3T3 cells. Int J Cancer 1996;65:221-9.
37. Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci USA 1984;81:3506-10.
38. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol 1985;135:2183-6.
39. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
40. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006;66:1261-4.
41. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
42. Lake DF, Huynh WC, Hersh EM. Natural and induced human antibody response to cancer. Cancer Invest 2000;18:480-9.
43. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988;41:562-7.
44. Kornstein MJ, Stewart R, Elder DE. Natural killer cells in the host response to melanoma. Cancer Res 1987;47:1411-2.
45. Cohen SA, Tzung SP, Doerr RJ, Goldrosen MH. Role of asialo-GM1 positive liver cells from athymic nude or polyinosinic-polycytidylic acid-treated mice in suppressing colon-derived experimental hepatic metastasis. Cancer Res 1990;50:1834-40.
46. Tzung SP, Cohen SA. Endogenous interferon alpha/beta produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor alpha production and interleukin-2-induced activation of nonparenchymal liver cells. Cancer Immunol Immunother 1991;34:150-6.
47. Rossen RD, Crane MM, Morgan AC, Giannini EH, Giovanella BC, Stehlin JS, Twomey JJ, Hersh EM. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer Res 1983;43:422-9.
48. Gupta RK, Leitch AM, Morton DL. Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. Cancer Immunol Immunother 1983;16:40-7.
49. The TH, van der Giessen M, Huiges HA, Schraffordt Koops H, van Wingerden I. Immune complexes in peripheral blood polymorphonuclear leucocytes of malignant melanoma patients. Clin Exp Immunol 1978;32:387-91.
50. Canevari S, Pupa SM, Ménard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 1996;7:227-32 (review)
51. Vlock DR, DerSimonian R, Kirkwood JM. Prognostic role of antibody reactivity to melanoma. J Clin Invest 1986;77:1116-21.
52. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-70.
53. Litvak DA, Gupta RK, Yee R, Wanek LA, Ye W, Morton DL. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. J Am Coll Surg 2004;198:27-35.
54. Gupta RK. Circulating immune complexes in malignant melanoma. Dis Markers 1988;6:81-95.
55. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20.
56. Pardoll DM. Cancer vaccines. Nat Med 1998;4:525-31.